CA
ABCL icon

Cetera Advisors’s AbCellera Biologics ABCL Stock Holding History

Cetera Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$102K Sell
22,445
-193
-0.9% -$985 ﹤0.01% 2304
2023
Q4 		$129K Buy
22,638
+1,672
+8% +$7.75K ﹤0.01% 1685
2023
Q3 		$96.4K Buy
20,966
+4,689
+29% +$28.5K ﹤0.01% 1604
2023
Q2 		$105K Buy
16,277
+5,418
+50% +$37K ﹤0.01% 1569
2023
Q1 		$81.9K Sell
10,859
-2,789
-20% -$25.3K ﹤0.01% 1578
2022
Q4 		$138K Buy
+13,648
New +$158K ﹤0.01% 1485

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Cetera Advisors's ABCL Position: Q1 2024 in Review

Cetera Advisors reduced its AbCellera Biologics (ABCL) stake by 0.85% in Q1 2024, selling an estimated $985 and leaving 22,445 shares worth $102K. The position accounts for ﹤0.01% of the portfolio, ranked #2304.

Cetera Advisors first reported a position in ABCL in Q4 2022 and has held it in 6 quarters since. The position peaked at $138K in Q4 2022. 154 funds tracked by Wall St. Rank hold ABCL as of Q1 2024.

  • Cetera Advisors held 22,445 shares of AbCellera Biologics worth $102K as of Q1 2024.
  • Cetera Advisors sold 193 AbCellera Biologics shares in Q1 2024, an estimated $985.
  • AbCellera Biologics made up ﹤0.01% of Cetera Advisors's portfolio in Q1 2024, its #2304 holding.
  • Cetera Advisors first reported a position in AbCellera Biologics in Q4 2022 and has held it in 6 quarters since.
  • Cetera Advisors's AbCellera Biologics position peaked at $138K in Q4 2022.
  • 154 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2024.

Based on Cetera Advisors's 13F filing for Q1 2024, filed 15 May 2024.